ACRS · Aclaris Therapeutics, Inc. · Executive Compensation
$3.48
-0.02 (-0.57%)
At close · Nov 20
Return incl. dividend (before tax)
Q1 2024 earnings call transcript
Market Cap
$555.14M
Shares
158.61M
Volume · Nov 19
1.89M
Avg daily vol (3M)
3.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Neal Walker | Chief Executive Officer | $3,375,591 |
| Kevin Balthaser | Chief Financial Officer | $1,490,790 |
| James Loerop | Chief Business Officer | $1,447,106 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Neal Walker | Chief Executive Officer | $1,445,135 |
| Kevin Balthaser | Chief Financial Officer | $1,102,163 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Douglas Manion | Former President and Chief Executive Officer | $7,157,681 |
| Gail Cawkwell | Former Chief Medical Officer | $2,403,312 |
| Kevin Balthaser | Chief Financial Officer | $2,344,432 |
| James Loerop | Chief Business Officer | $2,332,912 |
| Joseph Monahan | Chief Scientific Officer | $2,255,344 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gail Cawkwell | Former Chief Medical Officer | $3,299,008 |
| Douglas Manion | Former President and Chief Executive Officer | $3,202,198 |
| Joseph Monahan | Chief Scientific Officer | $2,822,982 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Neal Walker | President and Chief Executive Officer | $6,854,936 |
| Joseph Monahan | Chief Scientific Officer | $5,327,305 |
| Kamil Ali-Jackson | Former Chief Legal Officer | $4,687,106 |
| Frank Ruffo | Chief Financial Officer | $3,262,768 |
| David Gordon | Former Chief Medical Officer | $2,921,109 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Neal Walker | President and Chief Executive Officer | $1,610,678 |
| Frank Ruffo | Chief Financial Officer | $811,609 |
| Kamil Ali-Jackson | Former Chief Legal Officer | $767,574 |
| David Gordon | Former Chief Medical Officer | $760,225 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Neal Walker | President and Chief Executive Officer | $3,149,533 |
| David Gordon | Former Chief Medical Officer | $1,372,176 |
| Frank Ruffo | Chief Financial Officer | $1,162,390 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| William Humphries | directors on the Board | Appointed | 2025-06-05 |
| Andrew Schiff, M.D. | directors on the Board | Appointed | 2025-06-05 |
| Neal Walker | directors on the Board | Appointed | 2025-06-05 |
| Steven Knapp | Executive Vice President, Head of Regulatory & Quality | Appointed | 2024-11-18 |
| Hugh Davis | President and Chief Operating Officer | Appointed | 2024-11-18 |
| Hugh Davis | Class III director | Appointed | 2024-11-18 |
| Hugh Davis | President and Chief Operating Officer | Appointed | 2024-11-18 |
|
Andrew Powell
“Mr. Powell’s resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the board of directors | Resigned | 2024-03-19 |
| Gail Cawkwell, M.D., PhD. | Chief Medical Officer | Terminated | 2024-02-05 |
| Neal Walker | Interim Chief Executive Officer and President | Appointed | 2024-01-19 |
|
Douglas Manion
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
|
Director | Resigned | 2024-01-19 |
|
Douglas Manion
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
|
Chief Executive Officer and President | Resigned | 2024-01-19 |
| Kevin Balthaser | Chief Financial Officer | Appointed | 2023-01-06 |
| Douglas Manion | Chief Executive Officer | Appointed | 2023-01-06 |
| Kevin Balthaser | Chief Financial Officer | Appointed | 2022-11-22 |
| Douglas Manion | Class I director | Appointed | 2022-11-22 |
| Douglas Manion | Chief Executive Officer | Appointed | 2022-11-22 |
|
Frank Ruffo
“Mr. Ruffo’s retirement was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Financial Officer and Corporate Secretary | Retired | 2022-11-22 |
| Neal Walker | Chair of the Board | Appointed | 2022-11-22 |
|
Neal Walker
“Dr. Walker’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Executive Officer | Resigned | 2022-11-22 |
| Douglas Manion | President and Chief Operating Officer | Appointed | 2022-08-01 |
| Kamil Ali-Jackson | Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary | Retired | 2021-11-02 |
Leadership
- Neal Walker CEO, Chairman, Board Member
- Kevin Balthaser CFO
- Douglas Manion COO, Board Member
- Douglas Manion, M.D., FRCP (C) COO
- Hugh Davis COO, Board Member
- Andrew Schiff, M.D. Board Member
- Vincent Milano Board Member
- William Humphries Board Member
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
182 filings
159 filers
Visit website
Investor relations